Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues 2025
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Epithelial−Mesenchymal Transition in EGFR-TKI Acquired Resistant Lung Adenocarcinoma

HIDETAKA URAMOTO, TERUO IWATA, TAKAMITSU ONITSUKA, HIDEHIKO SHIMOKAWA, TAKESHI HANAGIRI and TSUNEHIRO OYAMA
Anticancer Research July 2010, 30 (7) 2513-2517;
HIDETAKA URAMOTO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hidetaka@med.uoeh-u.ac.jp
TERUO IWATA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKAMITSU ONITSUKA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HIDEHIKO SHIMOKAWA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TAKESHI HANAGIRI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TSUNEHIRO OYAMA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 30 no. 7 2513-2517
PubMed 
20682976

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received April 27, 2010
  • Revision received May 17, 2010
  • Accepted May 21, 2010
  • Published online August 3, 2010.

Copyright & Usage 
Copyright© 2010 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. HIDETAKA URAMOTO1,
  2. TERUO IWATA1,
  3. TAKAMITSU ONITSUKA1,
  4. HIDEHIKO SHIMOKAWA1,
  5. TAKESHI HANAGIRI1 and
  6. TSUNEHIRO OYAMA2
  1. 1Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
  2. 2Department of Environmental Health, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan
  1. Correspondence to: Hidetaka Uramoto, Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, 1-1 Iseigaoka, Yahatanishi-ku, Kitakyushu 807-8555, Japan, Tel: +81 936917442, Fax: +81 936924004, e-mail: hidetaka{at}med.uoeh-u.ac.jp
View Full Text

Statistics from Altmetric.com

Cited By...

  • 155 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research: 30 (7)
Anticancer Research
Vol. 30, Issue 7
July 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Epithelial−Mesenchymal Transition in EGFR-TKI Acquired Resistant Lung Adenocarcinoma
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
17 + 3 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Epithelial−Mesenchymal Transition in EGFR-TKI Acquired Resistant Lung Adenocarcinoma
HIDETAKA URAMOTO, TERUO IWATA, TAKAMITSU ONITSUKA, HIDEHIKO SHIMOKAWA, TAKESHI HANAGIRI, TSUNEHIRO OYAMA
Anticancer Research Jul 2010, 30 (7) 2513-2517;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Epithelial−Mesenchymal Transition in EGFR-TKI Acquired Resistant Lung Adenocarcinoma
HIDETAKA URAMOTO, TERUO IWATA, TAKAMITSU ONITSUKA, HIDEHIKO SHIMOKAWA, TAKESHI HANAGIRI, TSUNEHIRO OYAMA
Anticancer Research Jul 2010, 30 (7) 2513-2517;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • Acknowledgements
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • FGFR Inhibition Overcomes Resistance to EGFR-targeted Therapy in Epithelial-like Cutaneous Carcinoma
  • Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models
  • A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components
  • Integrative Omics Analysis Reveals Soluble Cadherin-3 as a Survival Predictor and an Early Monitoring Marker of EGFR Tyrosine Kinase Inhibitor Therapy in Lung Cancer
  • CXCR7 Reactivates ERK Signaling to Promote Resistance to EGFR Kinase Inhibitors in NSCLC
  • Engineering Multidimensional Evolutionary Forces to Combat Cancer
  • Circulating cell-free plasma tumour DNA shows a higher incidence of EGFR mutations in patients with extrathoracic disease progression
  • Expression of Neuroendocrine Factor VGF in Lung Cancer Cells Confers Resistance to EGFR Kinase Inhibitors and Triggers Epithelial-to-Mesenchymal Transition
  • The neuropilin 2 isoform NRP2b uniquely supports TGF{beta}-mediated progression in lung cancer
  • Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors
  • Intratumoral Heterogeneity in EGFR-Mutant NSCLC Results in Divergent Resistance Mechanisms in Response to EGFR Tyrosine Kinase Inhibition
  • Loss of MIG6 Accelerates Initiation and Progression of Mutant Epidermal Growth Factor Receptor-Driven Lung Adenocarcinoma
  • Gefitinib-mediated Reactive Oxygen Specie (ROS) Instigates Mitochondrial Dysfunction and Drug Resistance in Lung Cancer Cells
  • Metformin Sensitizes EGFR-TKI-Resistant Human Lung Cancer Cells In Vitro and In Vivo through Inhibition of IL-6 Signaling and EMT Reversal
  • A Phase I, Pharmacokinetic, and Pharmacodynamic Study of Panobinostat, an HDAC Inhibitor, Combined with Erlotinib in Patients with Advanced Aerodigestive Tract Tumors
  • Emerging Paradigms in the Development of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
  • Response to Erlotinib in Patients with EGFR Mutant Advanced Non-Small Cell Lung Cancers with a Squamous or Squamous-like Component
  • Prognostic Value of Aquired Resistance-related Molecules in Japanese Patients with NSCLC Treated with an EGFR-TKI
  • Complex Role of Histone Deacetylase Inhibitors in the Treatment of Non-Small-Cell Lung Cancer
  • Biomarkers for EGFR-Antagonist Response: In the Genes and on the Genes!
  • The Expression of CD146 Predicts a Poor Overall Survival in Patients with Adenocarcinoma of the Lung
  • The EMT Status in the Primary Tumor Does Not Predict Postoperative Recurrence or Disease-free Survival in Lung Adenocarcinoma
  • Molecular Diagnosis of MACC1 Status in Lung Adenocarcinoma by Immunohistochemical Analysis
  • Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors
  • Lack of Direct Association between EGFR Mutations and ER Beta Expression in Lung Cancer
  • Immunohistochemical Staining with DeltaNp63 Is Useful for Distinguishing the Squamous Cell Component of Adenosquamous Cell Carcinoma of the Lung
  • Google Scholar

More in this TOC Section

  • Association of Interleukin-12A Genotypes With Nasopharyngeal Carcinoma Risk
  • Immunogenicity of Neoantigens in Colorectal Cancer: Potential Influence of Tumor Mutation Burden, Stages, and Metastasis
  • Tissue Prognostic Markers for Clear Cell Renal Cell Carcinoma Tumor-stroma Interaction: Impact on TNM Staging Parameters
Show more Experimental Studies

Similar Articles

Anticancer Research

© 2025 Anticancer Research

Powered by HighWire